SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Liberalism: Do You Agree We've Had Enough of It?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Kenneth E. Phillipps who wrote (98888)1/29/2011 11:25:43 AM
From: Hope Praytochange   of 224748
 
Bears Rule Regular Session as Consumer Sentiment, Earnings Weigh 01/28 12:48 PM


12:48 PM Eastern Standard Time, 01/28/2011 (MidnightTrader) -- Bears are out in force at mid-day as losses at the major US indexes deepened following disappointing earnings results from Ford (F), Microsoft (MSFT:$27.751,0$-1.119,0-3.88%) and Amazon.com (AMZN:$171.14,00$-13.31,00-7.22%) . A drop in consumer sentiment also weighed on the markets, as well as unrest in Egypt. In the latest economic data, the Thomson Reuters/University of Michigan consumer sentiment index fell to 74.2 from 74.5 in December. Also, real gross domestic product, the broadest measure of the U.S economy, rose at a 3.2% annualized rate in the fourth quarter, up from a 2.6% rate in the third quarter. Economists polled by MarketWatch expected Q4 GDP to rise of 3.5%. On the upside, consumer spending rose at a 4.4% annual rate in the final three months of the year, the fastest pace since the first quarter of 2006. Inventories were a big drag on growth in the fourth quarter but this was largely offset by a positive contribution from net exports. For the year, GDP advanced 2.9%, compared with a 2.6% drop in 2009. This is the strongest growth rate in five years. In company news: ADRs of Sanofi-Aventis (SNY:$33.3500,$-1.9000,-5.39%) are down after the drug maker saw disappointing results from an experiment breast cancer drug it was developing. Sanofi's BSI-201 did not slow a certain type of aggressive breast tumor, Sanofi said in a statement. The news comes as a setback for Sanofi, which has been trying to acquire Genzyme (GENZ:$71.10,00$-0.18,00-0.25%) . Borders (BGP:$0.8489,$0.0429,5.32%) is up sharply after it said late Thursday it has received a commitment from GE Capital, Restructuring Finance to provide a $550 million senior secured credit facility. Upon completion, it will include $125 million of additional junior debt financing via the conversion of vendor payables and/or external sources

kennycanary mute deaf ??????????
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext